<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10155">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02974751</url>
  </required_header>
  <id_info>
    <org_study_id>TP0118</org_study_id>
    <nct_id>NCT02974751</nct_id>
  </id_info>
  <brief_title>Global Post-Market Registry Using Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue</brief_title>
  <acronym>OPEN WATER</acronym>
  <official_title>Global Post-Market Registry Using Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PROCEPT BioRobotics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PROCEPT BioRobotics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of the AQUABEAM System for the
      treatment of Lower Urinary Tract Symptoms (LUTS) resulting from Benign Prostatic Hyperplasia
      (BPH).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>February 2017</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>IPSS score change</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>BPH</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Aquablation</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with lower urinary tract symptoms, including those with urinary retention,
        who meet all other enrollment criteria.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male

          -  Subject has diagnosis of lower urinary tract symptoms due to benign prostatic
             enlargement causing bladder outlet obstruction or in urinary retention

          -  Prostate size ≥ 20 mL and ≤ 150 mL as measure by TRUS

          -  Patient is mentally capable and willing to sign a study-specific informed consent
             form

        Exclusion Criteria:

          -  Patients unable to stop anticoagulants, antiplatelet agents, or non-steroidal
             anti-inflammatory agents (NSAIDs, including aspirin greater or equal to 100mg) prior
             to treatment per standard of care

          -  History of gross haematuria

          -  Participants using systemic immune-suppressants including corticosteroids (except
             inhalants), known coagulopathy, or platelet disorder (except aspirin below 100mg/d)

          -  Contraindication to both general and spinal anesthesia

          -  Any severe illness that would prevent complete study participation or confound study
             results

          -  Subject is unwilling to accept a transfusion should one be required
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rachel Holman</last_name>
    <email>r.holman@procept-biorobotics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Angela Lee</last_name>
    <email>a.lee@procept-biorobotics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Frimley Park Hospital</name>
      <address>
        <city>Frimley</city>
        <state>Surrey</state>
        <zip>GU16 7UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 23, 2016</lastchanged_date>
  <firstreceived_date>November 23, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
